Rotkreuzklinikum München

Hospital


Location: München, Germany (DE) DE

ISNI: 0000000404801286

ROR: https://ror.org/04janzm11

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11 (2021) Gaza A, Fritz V, Malek L, Wormser L, Treiber N, Danner J, Kremer AE, et al. Journal article Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials (2021) Villegas SL, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, et al. Journal article Combined de‐repression of chemoresistance associated mitogen‐activated protein kinase 14 and activating transcription factor 2 by loss of microrna‐622 in hepatocellular carcinoma (2021) Fritz V, Malek L, Gaza A, Wormser L, Appel M, Kremer A, Thasler WE, et al. Journal article Appendicitis during the COVID-19 lockdown: results of a multicenter analysis in Germany. (2021) Willms AG, Oldhafer KJ, Conze S, Thasler WE, Von Schassen C, Hauer T, Huber T, et al. Journal article Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer (2021) Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, et al. Journal article Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer (2021) Konecny GE, Hendrickson AE, Davidson TM, Winterhoff BJ, Ma S, Mahner S, Sehouli J, et al. Journal article Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA (2021) Marme F, Hanusch C, Furlanetto J, Denkert C, Link T, Untch M, Blohmer JU, et al. Conference contribution Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC (2020) Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, Zahm DM, et al. Journal article Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC) (2020) Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, et al. Conference contribution GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status (2020) Link T, Blohmer JU, Just M, Untch M, Stoetzer O, Fasching P, Schneeweiss A, et al. Conference contribution
1 2 3 4 5 ... 7